35 results
6-K
TAK
Takeda Pharmaceutical Co
2 Feb 24
Current report (foreign)
6:16am
arising from differences between the fixed prices and floating market prices of renewable energy in a virtual power purchase agreement and those … method. The key assumptions taken into account include forecasted renewable energy prices and the expected generation of the renewable energy
6-K
TAK
Takeda Pharmaceutical Co
1 Feb 24
Current report (foreign)
6:18am
in renewable energy or low carbon energy technology will enable us to reduce our greenhouse gas emissions; and other factors identified in Takeda’s most
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
1 Feb 24
Current report (foreign)
6:06am
energy conservation measures and future advancements in renewable energy or low carbon energy technology will enable us to reduce our greenhouse gas
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
30 Nov 23
Current report (foreign)
6:01am
conservation measures and future advancements in renewable energy or low carbon energy technology will enable us to reduce our greenhouse gas emissions
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
30 Oct 23
Current report (foreign)
6:02am
and future advancements in renewable energy or low carbon energy technology will enable us to reduce our greenhouse gas emissions; and other factors
6-K
gxnuy 70avi0n1hmqm
30 Oct 23
Current report (foreign)
6:02am
6-K
EX-99.1
vz7 lgaih
26 Oct 23
Current report (foreign)
6:20am
6-K
b3i67f9u7
1 Aug 23
Current report (foreign)
6:10am
6-K
EX-99.1
1yseny swxt6
27 Jul 23
Current report (foreign)
6:05am
6-K
EX-99.1
k7lzwsg3
6 Jul 23
Current report (foreign)
6:18am
6-K
EX-99.1
l8ftsdwlogettxwy
23 Jun 23
Current report (foreign)
6:13am
6-K
EX-99.1
sldim33g80rojum
30 May 23
Current report (foreign)
6:19am
6-K
EX-99.1
5dcer
30 May 23
Current report (foreign)
6:14am
6-K
EX-99.1
nf4 p9v6y612ssse
30 May 23
Current report (foreign)
6:11am
6-K
rvgutams7uq 9gd
11 May 23
Current report (foreign)
6:07am
6-K
EX-99.1
f0s3y9mqb6v
11 May 23
Current report (foreign)
6:07am
6-K
kp4s73 afcx
13 Dec 22
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
7:00am
6-K
EX-99.1
tx4xqqae
30 Nov 22
Current report (foreign)
6:28am
6-K
EX-99.1
magp50ramd1sm7x91
27 Oct 22
Current report (foreign)
6:01am